Institutional members access full text with Ovid®

Share this article on:

Vulvovaginal atrophy: new and upcoming approaches

Simon, James A. MD, CCD, FACOG, PC

doi: 10.1097/gme.0b013e3181924701

Department of Obstetrics and Gynecology, George Washington University School of Medicine, Women's Health & Research Consultants®, Washington, DC

Financial disclosure: Dr Simon has served as a consultant or on the advisory boards of Allergan (Irvine, CA), The Alliance for Better Bone Health (Cincinnati, OH), Ascend Therapeutics (Herndon, VA), Barr (Pomona, NY), Bayer (Leverkusen, Germany), BioSante (Lincolnshire, IL), Corcept Therapeutics, Inc (Menlo Park, CA), GlaxoSmithKline (Philadelphia, PA), KV Pharmaceutical Co (St Louis, MO), Meditrina Pharmaceuticals (Ann Arbor, MI), Merck (Whitehouse Station, NJ), Merrion Pharmaceuticals (Wilmington, NC), Nanma/Tripharma/Trinity (Glen Arm, MD), Novo Nordisk A/S (Bagsvrerd, Denmark), Novogyne (East Hanover, NJ), Pear Tree Pharmaceuticals (Cambridge, MA), QuatRx Pharmaceuticals (Ann Arbor, MI), Roche (Basel, Switzerland), Schering-Plough (Kenilworth, NJ), Sciele (Atlanta, GA), Solvay (Marietta, GA), Warner Chilcott (Rockaway, NJ), and Wyeth (Madison, NJ). He has received grant/research support from BioSante, Boehringer Ingelheim, (Ingelheim, Germany), FemmePharma (Wayne, PA), GlaxoSmithKline, Nanma/Tripharma/Trinity, Novartis (Basel, Switzerland), and Proctor and Gamble (Cincinnati, OH). He has also served on the speaker's bureaus of Ascend, Barr, Bayer, GlaxoSmithKline, KV Pharmaceutical Co, Merck, Novartis, Novogyne, Sciele, Warner Chilcott, and Wyeth.

©2009The North American Menopause Society